Long Term Follow-up for Participants Who Previously Received a Single Intravitreal Injection of MCO-010 Optogenetic Therapy in the STARLIGHT Study
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Sonpiretigene isteparvovec (Primary)
- Indications Stargardt disease
- Focus Adverse reactions
- Acronyms STARLIGHT study; SUSTAIN
- Sponsors Nanoscope Therapeutics
Most Recent Events
- 24 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 26 Sep 2023 New trial record